Skip to content
Clinical Trial Events
19th Clinical Trials on Alzheimer's Disease (CTAD) 2026

Talk

Oral Communications

Wed, Nov 18, 2026 · 4:00–5:00 PM EST Ballroom - 4th floor, Boston Marriott Copley Place

About this session

Oral communications: OC36 Beyond amyloid and tau: Hippocampal volume and cognitive performance in the AHEAD-345 Study screening cohort; OC37 Comparison of MK6240, Flortaucipir, PI2620 and RO948 tau PET tracers and plasma pTau217 across the Alzheimer's disease continuum; OC38 Characterization of US Real-World Patients Receiving Donanemab with Modified Titration Using the NeuroDiscovery AI Database and the ALZ-NET Registry; OC39 Combining Plasma p-Tau217 with Proteomic Signatures Enables Graded Risk Stratification for Alzheimer's Disease Progression.

Speakers